[go: up one dir, main page]

AR057908A1 - Proceso para preparar montelukast e intermediarios del mismo - Google Patents

Proceso para preparar montelukast e intermediarios del mismo

Info

Publication number
AR057908A1
AR057908A1 ARP060105062A ARP060105062A AR057908A1 AR 057908 A1 AR057908 A1 AR 057908A1 AR P060105062 A ARP060105062 A AR P060105062A AR P060105062 A ARP060105062 A AR P060105062A AR 057908 A1 AR057908 A1 AR 057908A1
Authority
AR
Argentina
Prior art keywords
intermediaries
same
prepare montelukast
montelukast
prepare
Prior art date
Application number
ARP060105062A
Other languages
English (en)
Inventor
Arjanne Overeem
Lambertus Thijs
Petr Benovsky
Jakub Castulik
Jie Zhu
Petr Bartos
Radomir Skoumal
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR057908A1 publication Critical patent/AR057908A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Un proceso de metilacion reductiva, en donde se hace reaccionar cloruro, yoduro o bromuro de metil magnesio con un compuesto de formula (1), (2), (3) o (4), en donde dicha reaccion es llevada a cabo en presencia de una sal de cerio (III).
ARP060105062A 2005-11-18 2006-11-17 Proceso para preparar montelukast e intermediarios del mismo AR057908A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73775205P 2005-11-18 2005-11-18
US79442906P 2006-04-24 2006-04-24
US82438206P 2006-09-01 2006-09-01

Publications (1)

Publication Number Publication Date
AR057908A1 true AR057908A1 (es) 2007-12-26

Family

ID=37685804

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060105063A AR057909A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
ARP060105061A AR056815A1 (es) 2005-11-18 2006-11-17 PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
ARP060105062A AR057908A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast e intermediarios del mismo

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP060105063A AR057909A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
ARP060105061A AR056815A1 (es) 2005-11-18 2006-11-17 PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST

Country Status (12)

Country Link
US (5) US7786138B2 (es)
EP (3) EP1960362A1 (es)
JP (1) JP2009515922A (es)
AR (3) AR057909A1 (es)
AT (1) ATE497493T1 (es)
AU (3) AU2006314728A1 (es)
CA (3) CA2598093A1 (es)
DE (1) DE602006019979D1 (es)
IL (1) IL185129A0 (es)
NO (1) NO20074188L (es)
PT (1) PT1954679E (es)
WO (3) WO2007057225A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054317A1 (en) * 2004-11-19 2006-05-26 Matrix Laboratories Ltd Process for the preparation of novel amorphous montelukast sodium
WO2007005965A1 (en) 2005-07-05 2007-01-11 Teva Paharmaceutical Industries Ltd. Purification of montelukast
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP2014650A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process and intermediate for the production of an intermediate in the production of montelukast
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
TWI450275B (zh) * 2010-05-19 2014-08-21 Wistron Corp 可提升寫入保護之記憶體系統及相關方法
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000836A1 (en) * 1985-08-06 1987-02-12 Boehringer Biochemia Robin S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines
CA2038178A1 (en) 1990-04-05 1991-10-06 Carl C. Greco Niobium alkoxyalkoxides and process for formation
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0480716A1 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
EP1678139B1 (en) 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
EP1708708A1 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
WO2006008751A2 (en) * 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.

Also Published As

Publication number Publication date
AU2006314726A1 (en) 2007-05-24
PT1954679E (pt) 2011-05-05
CA2598093A1 (en) 2007-05-24
NO20074188L (no) 2008-08-13
AU2006314728A1 (en) 2007-05-24
EP1954679A1 (en) 2008-08-13
WO2007057228A1 (en) 2007-05-24
US20070135480A1 (en) 2007-06-14
AU2006314729A1 (en) 2007-05-24
CA2629840A1 (en) 2007-05-24
WO2007057227A1 (en) 2007-05-24
AR056815A1 (es) 2007-10-24
US20100099879A1 (en) 2010-04-22
AR057909A1 (es) 2007-12-26
IL185129A0 (en) 2007-12-03
EP1948610A2 (en) 2008-07-30
WO2007057225A2 (en) 2007-05-24
US20090093636A1 (en) 2009-04-09
US20070135643A1 (en) 2007-06-14
DE602006019979D1 (de) 2011-03-17
ATE497493T1 (de) 2011-02-15
EP1954679B1 (en) 2011-02-02
US7476748B2 (en) 2009-01-13
JP2009515922A (ja) 2009-04-16
WO2007057225A3 (en) 2007-07-26
EP1960362A1 (en) 2008-08-27
US7786138B2 (en) 2010-08-31
CA2629834A1 (en) 2007-05-24
US7601741B2 (en) 2009-10-13
US20070135642A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
AR057908A1 (es) Proceso para preparar montelukast e intermediarios del mismo
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
IL181529A0 (en) Diagnostic compounds
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
AR087794A1 (es) Proceso para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]-piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo, intermediarios de dicha sintesis y proceso para prepararlos
TW200728280A (en) Anthracene derivative
AR069493A1 (es) Mejora del proceso usando tmeda
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CL2012000114A1 (es) Proceso para la preparacion de compuestos derivados de 5-amino-benzonorbornadieno donde se hacer reaccionar un compuesto de 5-halo-benzonorbornadieno con una bencilamina en prensecia de un catalizador de paladio.
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
EP1999720A4 (en) METHOD FOR MODELING THE INTERACTION BETWEEN DEFORMABLE OBJECTS
AR074545A1 (es) Proceso de preparacion de dihidroetorfina
AR044019A1 (es) Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
CR8275A (es) 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS
BR0309087A (pt) Processos de preparação de combretastatinas
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
CY1114020T1 (el) 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης
UY30009A1 (es) Compuestos benzoilpirazol y herbicidas que los contienen
TW200728310A (en) Process for the preparation of ferri-succinylcasein
PL1848661T3 (pl) Sposób wytwarzania chloru lub chloranu sodu
AR063597A1 (es) Nueva sal
AR077457A1 (es) Intermediarios y proceso de preparacion de 4-(acetilamino)-3-[(4-cloro-fenil)tio]-2-metil-1h-indol-1-acetico
BRPI0411717A (pt) processo para a preparação de acilsulfamoibenzamidas
TW200801011A (en) New compounds II

Legal Events

Date Code Title Description
FA Abandonment or withdrawal